Tonix Pharmaceuticals Holding Corp (TNXP)

Healthcare | Biotechnology
Income Statement (Quarterly) 2025-03-31 2024-12-31 2024-09-30 2024-06-30
Revenue 2,429,000 2,582,000 2,822,000 2,208,000
Cost of Revenue 943,000 1,183,000 1,555,000 3,367,000
Gross Profit 1,486,000 1,399,000 1,267,000 -1,159,000
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 10,104,000 15,582,000 7,707,000 7,502,000
Operating Expenses 17,540,000 23,879,000 16,821,000 17,200,000
Operating Income -16,054,000 -22,480,000 -15,554,000 -18,359,000
Interest Expense 0 0 0 0
Income Before Tax 0 -22,108,000 -14,213,000 -78,776,000
Income Tax Expense 0 43,000 0 0
Net Income 0 -22,108,000 -14,213,000 -78,776,000
Per Share
EPS -2.84 -977.00 -23.00 -1,928.00
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue 10,094,000 7,768,000 0 0 0
Cost of Revenue 7,765,000 4,741,000 112,091,000 0 0
Gross Profit 2,329,000 3,027,000 -112,091,000 0 0
Operating Expenses
R&D Expenses 0 0 0 0 0
SG&A Expenses 40,101,000 34,752,000 30,215,000 0 14,354,000
Operating Expenses 80,073,000 121,407,000 112,091,000 92,312,000 50,511,000
Operating Income -77,744,000 -118,380,000 -112,091,000 -92,312,000 -50,511,000
Interest Expense 0 0 -7,912,000 0 0
Income Before Tax -130,036,000 -116,658,000 -110,218,000 0 -50,463,000
Income Tax Expense -1,167,000 0 4,786,000 0 0
Net Income -130,036,000 -116,658,000 -115,004,000 -92,287,000 -50,463,000
Per Share
EPS -3,504.00 -6,368.84 -20.11 -0.98 -0.55
EPS Diluted 0.00 0.00 0.00 0.00 0.00
Balance Sheet (Quarterly) 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Assets
Cash and Cash Equivalents 98,776,000 24,948,000 120,229,000 178,660,000
Short Term Investments 0 0 0 0
Net Receivables 7,904,000 4,590,000 8,043,000 7,726,000
Inventory 8,408,000 14,147,000 -8,043,000 0
Total Current Assets 119,002,000 47,768,000 130,777,000 189,049,000
Property Plant Equipment 42,817,000 94,852,000 94,529,000 51,472,000
Goodwill and Intangibles 120,000 10,708,000 120,000 0
Total Assets 162,890,000 154,457,000 225,690,000 240,900,000
Liabilities
Account Payables 4,546,000 3,782,000 8,068,000 0
Short Term Debt 3,368,000 2,620,000 432,000 489,000
Total Current Liabilities 18,307,000 18,884,000 18,180,000 21,716,000
Long Term Debt 5,025,000 7,193,000 328,000 467,000
Total Liabilities 23,332,000 48,932,000 18,508,000 22,183,000
Shareholders Equity
Retained Earnings -730,694,000 -600,658,000 -470,038,000 -359,820,000
Total Shareholders Equity 139,558,000 105,525,000 207,182,000 218,717,000
Balance Sheet (Annual) 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Assets
Cash and Cash Equivalents 98,776,000 24,948,000 120,229,000 178,660,000 77,068,000
Short Term Investments 0 0 0 0 0
Net Receivables 7,904,000 4,590,000 8,043,000 7,726,000 7,627,000
Inventory 8,408,000 14,147,000 -8,043,000 0 0
Total Current Assets 119,002,000 47,768,000 130,777,000 189,049,000 87,989,000
Property Plant Equipment 42,817,000 94,852,000 94,529,000 51,472,000 9,829,000
Goodwill and Intangibles 120,000 10,708,000 120,000 0 120,000
Total Assets 162,890,000 154,457,000 225,690,000 240,900,000 98,183,000
Liabilities
Account Payables 4,546,000 3,782,000 8,068,000 0 4,598,000
Short Term Debt 3,368,000 2,620,000 432,000 489,000 595,000
Total Current Liabilities 18,307,000 18,884,000 18,180,000 21,716,000 9,819,000
Long Term Debt 5,025,000 7,193,000 328,000 467,000 0
Total Liabilities 23,332,000 48,932,000 18,508,000 22,183,000 10,535,000
Shareholders Equity
Retained Earnings -730,694,000 -600,658,000 -470,038,000 -359,820,000 -267,533,000
Total Shareholders Equity 139,558,000 105,525,000 207,182,000 218,717,000 87,648,000
Cash Flow Statement (Quarterly) 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Activities
Net Income -130,036,000 -116,658,000 -110,218,000 -92,287,000
Depreciation & Amortization 3,421,000 4,291,000 1,253,000 0
Stock Based Compensation 4,778,000 9,348,000 10,914,000 7,899,000
Change in Working Capital 5,775,000 -35,000 -2,000 5,781,000
Operating Cash Flow -60,925,000 -102,003,000 -98,053,000 0
Investing Activities
Capital Expenditure -120,000 -7,895,000 -48,147,000 -35,307,000
Investments -120,000 -7,895,000 -48,147,000 -35,307,000
Investing Cash Flow -120,000 -29,070,000 -48,147,000 0
Financing Activities
Debt Repayment -2,350,000 -8,942,000 0 0
Common Stock Issued/Repurchased 140,195,000 36,517,000 47,213,000 212,389,000
Dividends Paid 0 0 -6,659,000 0
Financing Cash Flow 134,872,000 36,517,000 87,844,000 212,487,000
Summary
Free Cash Flow -61,045,000 -109,898,000 -146,200,000 -110,864,000
Net Change in Cash 73,831,000 -95,281,000 -58,430,000 212,487,000
Cash Flow Statement (Annual) 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Operating Activities
Net Income -130,036,000 -116,658,000 -110,218,000 -92,287,000 -50,463,000
Depreciation & Amortization 3,421,000 4,291,000 1,253,000 0 27,000
Stock Based Compensation 4,778,000 9,348,000 10,914,000 7,899,000 2,876,000
Change in Working Capital 5,775,000 -35,000 -2,000 5,781,000 -2,366,000
Operating Cash Flow -60,925,000 -102,003,000 -98,053,000 0 -48,566,000
Investing Activities
Capital Expenditure -120,000 -7,895,000 -48,147,000 -35,307,000 -8,564,000
Investments -120,000 -7,895,000 -48,147,000 -35,307,000 -8,564,000
Investing Cash Flow -120,000 -29,070,000 -48,147,000 0 -8,564,000
Financing Activities
Debt Repayment -2,350,000 -8,942,000 0 0 0
Common Stock Issued/Repurchased 140,195,000 36,517,000 47,213,000 212,389,000 108,605,000
Dividends Paid 0 0 -6,659,000 0 451,000
Financing Cash Flow 134,872,000 36,517,000 87,844,000 212,487,000 123,105,000
Summary
Free Cash Flow -61,045,000 -109,898,000 -146,200,000 -110,864,000 -57,130,000
Net Change in Cash 73,831,000 -95,281,000 -58,430,000 212,487,000 65,959,000